In compliance with current regulations, let us know which audience you belong to:
Espansione Group, the leading medical device company offering screening and treatment solutions for ocular conditions, announced today the kick-off of LightWave I, its first multi-center clinical trial focused on non-neovascular (dry) Age-Related Macular Degeneration (AMD) through its patented technology Light Modulation™ Low-level Light Therapy (LM™ LLLT), a medical-grade photobiomodulation (PBM) technology globally certified already in over 50 countries.
Recruitment for the study has already started. The research will involve a total of 350 patients affected by dry AMD: of these 175 patients will receive a new LM™ LLLT protocol specifically developed for AMD by Espansione Group's scientific committee, while the remaining 175 patients will act as control group. This body of work will leverage LM™ LLLT, administered via eye-light® solution, in a partnership with 7 leading retinal diseases centers across the European continent and even more top-tier exponents of the scientific community:
The main visual and anatomical outcomes of the study will include changes of visual acuity, number and size of drusen, contrast sensitivity, as well as overall quality of life of patients involved.
ON AMD
Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The dry AMD subtype accounts for 85-90% of cases, with a global prevalence of 0.44%, increasing with age. Over 280 million people will be affected by 2040. With a global prevalence amongst the elderly, dry AMD is a multifactorial disease: age, genetics, race (most common for caucasians), smoking, obesity and cardiovascular diseases are the main factors playing a role in augmenting the risk of dry AMD arising.
SOURCE: SCHULTZ NM, ET AL. "GLOBAL BURDEN OF DRY AGE-RELATED MACULAR DEGENERATION: A TARGETED LITERATURE REVIEW." CLIN THER. 2021;43(10):1792-1818
About Espansione Group
Espansione Group is a pioneer in the medtech industry, on a mission to develop and market innovative, non-invasive solutions for prevention and management of conditions in ophthalmology and beyond.
The company’s certified medical solutions leverage proprietary technologies such as Light Modulation™ Low-level Light Therapy (LM™ LLLT) photobiomodulation (PBM), with an ambition to redefine standards of care by expanding on their applications, with a constant commitment to science, research and development, and customer excellence.
Strategic partnerships with the industry, a strong commitment to scientific excellence and a will to shape the future have enabled Espansione Group’s advanced medical technologies to be present in over 50 countries, serving thousands healthcare providers worldwide.
For more information, visit www.espansionegroup.it
Espansione Group Press Office
press@espansione.it
© 2022 Espansione Group, All Rights Reserved
Posted on October 6th, 2022 in Newsroom